Nov. 14, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics ...

Pre-earnings options volume in Rani Therapeutics (RANI) Holdings is normal with calls leading puts 15:2. Implied volatility suggests the market is anticipating a move near 12.6%, or 30c, after results ...

SAN JOSE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage ...

Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today ...

Interested parties can register for and access the live webcasts for these conferences by visiting the "Events” section of the Rani Therapeutics website. The webcast replays will be available after ...

Investing.com - Rani Therapeutics Holdings (NASDAQ: RANI) reported third quarter EPS of $-0.36, $0.07 better than the analyst estimate of $-0.43. Revenue for the quarter came in ...

On Monday, Stifel reaffirmed its Buy rating on shares of Rani Therapeutics Holdings (NASDAQ:RANI) with a steady price target of $10.00. The biopharmaceutical company has recently ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Shares of NASDAQ:RANI opened at $2.68 on Friday. Rani Therapeutics has a 12 month low of $1.82 and a 12 month high of $8.75. The company’s 50-day moving average price is $2.57 and its two ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...